M. Li et al., Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism, J HYPERTENS, 17(3), 1999, pp. 419-426
Citations number
34
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Objective To examine whether the increase of blood pressure in adrenocortic
otrophin-treated rats is mediated through mineralocorticoid or glucocortico
id receptors or corticosterone 6 beta-hydroxylation inhibition.
Design Rats were randomly allocated to 14 treatment groups for 10 days. The
treatments included sham injection (n = 35), adrenocorticotrophin (5, 100,
500 mu g/kg per day, subcutaneously, n = 5, 15 and 15, respectively), spir
onolactone (100 mg/kg per day, subcutaneously, n = 15), standard-dose or hi
gh-dose RU 486 (70 mg/kg every 3 days or 70 mg/kg per day, subcutaneously,
n = 5 and 10, respectively), spironolactone + adrenocorticotrophin (100 mu
g/kg per day, n = 5, or 500 mu g/kg per day, n = 10), standard-dose RU 486
+ adrenocorticotrophin (500 mu g/kg per day, n = 5), high-dose RU 486 + adr
enocorticotrophin (100 mu g/kg per day, n = 10), troleandomycin (40 mg/kg p
er day, subcutaneously, n = 5) and troleandomycin + adrenocorticotrophin (5
mu g/kg per day, n = 5). Systolic blood pressure and metabolic parameters
were measured every second day.
Results Adrenocorticotrophin treatment increased systolic blood pressure do
se-dependently (5 mu g/kg per day: +14 +/- 2 mmHg; 100 mu g/kg per day: +20
+/- 2 mmHg; 500 mu g/kg per day: +28 +/- 2 mmHg, all P < 0.001). Adrenocor
ticotrophin at 100 and 500 mu g/kg per day increased plasma sodium and decr
eased plasma potassium concentrations. Spironolactone did not block adrenoc
orticotrophin-induced systolic blood pressure changes but did block changes
in plasma sodium and potassium levels. Standard-dose RU 486 did not modify
the adrenocorticotrophin-induced (500 mu g/kg per day) systolic blood pres
sure rise but blocked the effect of adrenocorticotrophin on body weight Hig
h-dose RU 486 partially blocked the adrenocorticotrophin-induced (100 mu g/
kg per day) systolic blood pressure increase (adrenocorticotrophin at 100 m
u g/kg per day: 143 +/- 3 mmHg; high-dose RU 486 + adrenocorticotrophin at
100 mu g/kg per day: 128 +/- 5 mmHg, P < 0.001) and body-weight loss. Trole
andomycin did not alter the development of adrenocorticotrophin-induced hyp
ertension.
Conclusions Spironolactone and standard-dose RU 486 did not modify adrenoco
rticotrophin-induced hypertension despite demonstrable antimineralocorticoi
d and antiglucocorticoid actions. High-dose RU 486 partially blocked adreno
corticotrophin-induced (100 mu g/kg per day) hypertension, suggesting eithe
r a permissive effect of glucocorticoid on blood pressure or other antihype
rtensive actions of RU 486. Inhibition of glucocorticoid 6 beta-hydroxylati
on by troleandomycin did not modify adrenocorticotrophin-induced hypertensi
on, suggesting that effects of corticosterone 6 beta-hydroxylation in adren
ocorticotrophin-induced hypertension are negligible. J Hypertens 1999, 17:4
19-426 (C) Lippincott Williams & Wilkins.